By Lina carolina 
Basal cell carcinomas (BCCs), the most prevalent form of skin cancer, predominantly emerge in areas of the skin subjected to chronic sun exposure, with the face being a particularly common site. For locally advanced tumors, surgical intervention often presents significant challenges, frequently necessitating extensive procedures with potential for disfigurement and functional impairment. In a groundbreaking development, a collaborative research team from MedUni Vienna and University Hospital Vienna has unveiled promising results from a clinical study investigating a novel therapeutic approach. The study, published in the prestigious journal Nature Cancer, details how the active substance Talimogene Laherparepvec (TVEC) not only facilitated the surgical removal of BCCs by reducing their size but also achieved complete tumor regression in a subset of patients.
A Novel Approach to a Common Cancer
Basal cell carcinoma accounts for approximately 80% of all non-melanoma skin cancers, with an estimated 3.5 million new cases diagnosed annually in the United States alone. While generally slow-growing and rarely metastasizing, advanced BCCs, especially those occurring on the face, can infiltrate surrounding tissues, including cartilage and bone, making complete eradication surgically demanding. Traditional treatments for BCC include surgical excision, Mohs surgery, curettage and electrodesiccation, cryotherapy, and radiation therapy. However, for tumors that are extensive or have recurred after previous treatments, these modalities may lead to significant scarring, loss of function, and a compromised aesthetic outcome.
The innovation lies in the application of TVEC, a therapy previously approved for superficial melanoma metastases. TVEC is a genetically engineered oncolytic virus, a modified herpes simplex virus designed to selectively infect and destroy cancer cells while simultaneously stimulating the body’s own immune system to target the tumor. This dual mechanism of action offers a unique advantage in combating cancer. In the context of BCC, the research team hypothesized that pre-surgical (neoadjuvant) treatment with TVEC could shrink tumors, thereby simplifying the subsequent surgical procedure and minimizing the need for complex reconstructive surgeries such as skin grafts or flaps.
Study Design and Patient Population
The clinical trial enrolled 18 patients diagnosed with basal cell carcinoma that, due to its size and location, would have otherwise required significant reconstructive surgery. These patients were selected specifically because their tumors presented a substantial surgical challenge, posing a risk of functional or cosmetic deficits post-operation. The study protocol involved administering six intralesional injections of TVEC directly into the tumor over a 13-week period. Following this neoadjuvant therapy, the tumors were surgically removed.
The rationale behind this approach is rooted in the understanding of how oncolytic viruses work. By replicating within tumor cells, TVEC causes cell lysis, releasing tumor-associated antigens. These released antigens are then recognized by the immune system, triggering an inflammatory response and the activation of cytotoxic T lymphocytes, which are crucial for recognizing and destroying cancer cells. This "in situ vaccination" effect is believed to be a key component of TVEC’s efficacy, creating a systemic anti-tumor immune response that can target both the primary tumor and any micrometastases.
Promising Results: Tumor Reduction and Regression
The findings from this study are highly encouraging. According to the principal investigator, Christoph Höller, Head of the Skin Tumour Centre at the Department of Dermatology at MedUni Vienna, the results surpassed expectations. "This enabled the tumour to be reduced in size in half of the patients to such an extent that surgery with direct wound closure was possible," stated Dr. Höller. This significant reduction in tumor burden directly translated into less invasive surgical procedures for these patients, mitigating the need for extensive tissue reconstruction.
Furthermore, the therapeutic impact of TVEC extended beyond mere size reduction. In a remarkable one-third of the cases, the subsequent histological examination of the surgically removed tumors revealed no evidence of viable tumor cells. This suggests a complete eradication of the cancer in these individuals, a significant achievement for advanced BCCs. Crucially, the study reported that all treated tumors showed a reduction in size, and importantly, no tumor continued to grow during the course of the therapy, underscoring TVEC’s potent anti-cancer activity.
The safety and tolerability of the treatment were also highlighted. "The treatment was well tolerated by the patients," Dr. Höller affirmed. This is a critical factor in the adoption of any new therapeutic agent, particularly for conditions requiring prolonged or repeated treatments.
Implications for Surgical Outcomes and Patient Well-being
Julia Ressler, the first author of the study and also from the Department of Dermatology, emphasized the broader implications for patient care. "The new treatment option for basal cell carcinoma can not only simplify surgery, but also help to avoid disfiguring operations and functional limitations," she added. The ability to preserve healthy tissue and minimize scarring is paramount for patients, particularly when the affected area is the face, where appearance and facial function are so vital to quality of life.
The implications for surgical planning are substantial. For surgeons, a smaller, less invasive tumor means a more straightforward procedure with a higher likelihood of achieving clear margins, thereby reducing the risk of recurrence. For patients, it means less pain, a quicker recovery, and a better cosmetic outcome, potentially eliminating the need for complex and sometimes disfiguring reconstructive surgeries. This advancement represents a paradigm shift in how locally advanced BCCs might be managed, prioritizing less aggressive interventions and improved patient experience.
Unveiling the Immunological Mechanisms
Beyond the clinical observations, the research team conducted comprehensive analyses to understand the underlying immunological mechanisms at play. In collaboration with the St. Anna Children’s Hospital, these investigations revealed that TVEC therapy significantly enhances the immune defense within the tumor tissue. This finding provides crucial insights into how TVEC achieves its therapeutic effects, validating the hypothesis that it leverages the immune system to fight cancer.
The strengthening of the immune response within the tumor microenvironment suggests that TVEC not only directly kills cancer cells but also primes the immune system to recognize and attack them more effectively. This immune modulation could be responsible for the complete regressions observed in some patients and may also contribute to long-term disease control by establishing an immunological memory. Understanding these intricate interactions is vital for further optimizing the therapy and potentially combining it with other immunotherapeutic agents for even greater efficacy.
Future Directions and Broader Impact
The results of this study position TVEC as a highly promising neoadjuvant treatment for basal cell carcinoma, especially for patients who would otherwise face extensive surgical interventions. The researchers are optimistic about the potential of this therapy to become a standard of care for a specific subset of BCC patients.
"These results suggest that TVEC could be a promising option for the neoadjuvant, i.e. pre-surgical, treatment of basal cell carcinoma, particularly in patients for whom major surgery should be avoided," the article states. This neoadjuvant strategy offers a valuable alternative to immediate aggressive surgery, allowing for a more tailored and less burdensome treatment plan.
Looking ahead, further research is deemed essential to solidify these findings. "Further studies are to follow in order to confirm the benefits of this new option in a larger patient population," the researchers concluded. Larger, multi-center clinical trials will be crucial to confirm the efficacy, safety, and long-term outcomes of TVEC in a broader and more diverse patient group. Such studies will also help to define the optimal dosage, treatment duration, and patient selection criteria for this innovative therapy.
The successful application of TVEC in BCC treatment could have far-reaching implications for dermatology and oncology. It underscores the growing importance of oncolytic viruses and immunotherapy in cancer treatment, offering new hope for patients with difficult-to-treat cancers. The ability to reduce tumor burden non-invasively and harness the power of the immune system represents a significant leap forward in the ongoing battle against skin cancer. This research not only advances the treatment of basal cell carcinoma but also paves the way for exploring similar strategies for other types of skin cancers and potentially even other solid tumors. The publication in Nature Cancer signifies the high caliber and potential impact of this groundbreaking work on the global scientific community.
